10/08/2026 MoonLake announced Phase 3 results of Sonelokimab in Psoriatic Arthritis MoonLake announced Phase 3 results of Sonelokimab in Psoriatic Arthritis (Ref) MoonLake Immunotherapeutics announced positive topline results from the Phase 3, IZAR-1/ NCT06641076 trial evaluating sonelokimab in biologic-naïve adults with active psoriatic arthritis (PsA). The trial met all the clinical endpoint at week 16 for 60 mg sonelokimab with induction. The primary endpoint of ACR50 was

21/06/2026 MoonLake Immunotherapeutics announced Phase 3 results for sonelokimab in Hidradenitis Suppurativa MoonLake Immunotherapeutics announced Phase 3 results for sonelokimab in Hidradenitis Suppurativa (Ref) MoonLake Immunotherapeutics announced the week 52 results from its Phase 3, VELA-1 and VELA-2 trials of sonelokimab (SLK; IL-17 A/F inhibitor) for the treatment of patients with moderate-to-severe Hidradenitis Suppurativa (HS). At week 52, sonelokimab showed consiste

10/05/2026 MoonLake Immunotherapeutics announced a positive outcome from its final Pre-BLA meeting with the US FDA for sonelukimab in HS MoonLake Immunotherapeutics announced a positive outcome from its final Pre-BLA meeting with the US FDA for sonelukimab in HS (Ref) MoonLake Immunotherapeutics announced a positive outcome from its final pre-BLA meeting with the US FDA on the Hidradenitis suppurativa (HS) program for its Nanobody® sonelokimab (SLK; an inhibitor of IL-17A and

22/02/2026 MoonLake announced topline results from its Phase 2 study of sonelokimab in axial spondyloarthritis MoonLake announced topline results from its Phase 2 study of sonelokimab in axial spondyloarthritis ( Ref ) MoonLake Immunotherapeutics announced positive topline results from its Phase 2, S-OLARIS study evaluating sonelokimab (IL-17A and IL-17F inhibitor) in patients with radiographic and non-radiographic axial spondyloarthritis The study demonstrated a clinically m